Table 2.
Univariate comparison of clinical characteristics between the iVD and sVD groups.
| iVD group (n = 80) | sVD group (n = 36) | P | |
|---|---|---|---|
| Age (years): Median (IQR) | 9.7 (5.9–13.7) | 2.9 (1.9–4.5) | <0.001 |
| Male gender: n (%) | 46 (57.5%) | 19 (52.8%) | 0.689 |
| Vaccination: n (%) | 17 (21.3%) | 5 (13.9%) | 0.447 |
| Clinical symptoms: n (%) | |||
| Asymptomatic | 3 (3.8%) | 4 (11.1%) | 0.201 |
| Fever | 38 (47.5%) | 22 (61.1%) | 0.229 |
| Respiratory symptoms | 38 (47.5%) | 11 (30.6%) | 0.106 |
| Digestive symptoms | 10 (12.5%) | 4 (11.1%) | 1.000 |
| Imaging findings of pneumonia: n (%) | 11 (13.8%) | 6 (16.7%) | 0.778 |
| Positive SARS-CoV-2 IgM: n (%) | 1 (1.3%) | 2 (5.6%) | 0.227 |
| Positive SARS-CoV-2 IgG: n (%) | 56 (70.0%) | 18 (50.0%) | 0.059 |
25(OH)D, 25 hydroxyvitamin D; iVD, insufficient vitamin D; IQR, interquartile range; sVD, sufficient vitamin D; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.